FDA Approved: STIOLTO RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves a supplemental application for STIOLTO RESPIMAT, a fixed-dose inhaled combination of tiotropium and olodaterol, submitted by Boehringer Ingelheim P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Stiolto Respimat (tiotropium + olodaterol)

Snippet

SUPPL AP for STIOLTO RESPIMAT (TIOTROPIUM BROMIDE AND OLODATEROL)